Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology, and infectious disease diagnostics. Predicine is developing proprietary cell-free DNA- and cell-free RNA-based liquid biopsy technologies to enable minimally invasive molecular diagnosis for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring and disease progression.
Predicine is an internal clinical CSO (Contract Solution Organization) that provides first-in-class ctRNA and ctDNA combined liquid biopsy assay, to support global clinical trials, through Predicine's two CLIA certified service laboratories locates at San Francisco US, and Shanghai China. Currently three PrediSeq NGS panels are offered - Pan Cancer Panel, DNA Damage Repair Panel, and Cancer Immunotherapy Panel.